Obexelimab

Obexelimab (XmAb5871) is Zenas BioPharma's bifunctional antibody that binds CD19 on B cells while also engaging FcγRIIb, the only inhibitory Fc receptor. That dual engagement silences B cells and plasmablasts without depleting them. Zenas is running the molecule across four autoimmune indications: relapsing multiple sclerosis (Phase 2 MoonStone, NCT06564311) [1], IgG4-related disease (Phase 3, NCT05662241) [2], warm autoimmune hemolytic anemia (Phase 3 SApHiAre, NCT05786573) [3], and systemic lupus erythematosus (Phase 2, NCT06559163) [4]. MoonStone is a 93-patient trial in relapsing MS with new gadolinium-enhancing brain lesions as the primary endpoint, an MRI readout of active blood-brain-barrier disruption that lets small MS trials read out in months rather than years [1]. The commercial question is whether functional silencing is meaningfully different from CD20 depletion in a market already dominated by ocrelizumab, ofatumumab, and ublituximab. To be competitive, MoonStone needs to approach the ~89-96% lesion reduction ocrelizumab produced versus placebo in its Phase 2 [13] and the near-total suppression ublituximab showed in its Phase 2a [14]. Anything materially short of that puts obexelimab in a follower position in MS and leaves the Zenas equity story resting on the IgG4-RD and wAIHA orphan programs.

Novel compound. Never approved anywhere. Obexelimab originated at Xencor as XmAb5871 and was licensed to Zenas BioPharma, which IPO'd in September 2024 as ticker ZBIO with obexelimab as its sole clinical asset [5]. The MS program (MoonStone, NCT06564311) is Phase 2 and active-not-recruiting per ClinicalTrials.gov, with 93 patients enrolled [1]. No FDA breakthrough, fast track, or orphan designation has been publicly disclosed for the MS indication. The company's most advanced program is IgG4-related disease (Phase 3 INDIGO, NCT05662241, n=194, active-not-recruiting), which carries fast track designation and a full published protocol [2] [6]. Warm autoimmune hemolytic anemia (SApHiAre, NCT05786573, n=134) is at Phase 3 with orphan status [3]. SLE is at Phase 2 (NCT06559163, n=190, active-not-recruiting) [4]. Zenas's Q2 2026 10-Q filed on 2026-08-13 is the most recent authoritative source on timelines and cash runway [7]. Both MoonStone and INDIGO are expected to read out within a 12-month window in 2026, which makes Zenas a binary-outcome immunology name for the next several quarters. Cash burn on four parallel programs is real but currently well-funded (see risks). The MS trial is the least commercially defensible leg of that spend.

CD19 sits on the surface of every B cell except terminally differentiated plasma cells. It acts as a signal amplifier: when the B cell receptor detects an antigen, CD19 boosts the resulting activation signal [8]. FcγRIIb is the only inhibitory receptor in the Fc receptor family. When it gets pulled into a complex with an activating receptor, it delivers a stop signal that shuts the B cell down. Obexelimab is engineered so its Fc domain binds FcγRIIb with unusually high affinity while its antigen-binding arms grab CD19. On a B cell surface, that geometry drags CD19 and FcγRIIb into the same complex. The inhibitory signal wins. The B cell goes quiet, and the cell survives [9] [10]. The dominant B-cell therapies in autoimmunity (rituximab, ocrelizumab, ofatumumab, ublituximab, obinutuzumab) all target CD20 and kill B cells outright. That works, but depletion takes weeks to reverse, blunts vaccine responses, and raises infection risk. It also misses plasmablasts and short-lived plasma cells, which drop CD20 while keeping CD19 and continue producing pathogenic antibodies in IgG4-RD, wAIHA, and lupus. Obexelimab silences the CD20-negative plasmablast population that CD20 depletion misses [11]. In MS, where B cells drive relapses in part by presenting antigen to T cells rather than by antibody production, the plasmablast argument carries less weight. The open question is whether functional silencing of naive and memory B cells matches the near-complete depletion delivered by ocrelizumab. Human data so far in SLE and IgG4-RD show pharmacologic activity, not CD20-level efficacy [11] [12].

MoonStone (NCT06564311) is a Phase 2, randomized, double-blind, placebo-controlled trial of subcutaneous obexelimab in relapsing multiple sclerosis. Zenas enrolled 93 patients and the trial is now active-not-recruiting [1]. The primary endpoint is the cumulative number of new gadolinium-enhancing T1 hyperintense brain lesions on MRI over the treatment period. Gadolinium is a paramagnetic contrast agent injected intravenously before MRI. It cannot normally cross an intact blood-brain barrier, so brain tissue does not light up on the T1 sequence. In active MS, immune infiltration disrupts the barrier at the site of new demyelinating attacks, gadolinium leaks into the lesion, and the spot lights up as a bright focal enhancement on MRI. Each enhancing lesion is a snapshot of ongoing immune attack on myelin, so counting them gives a direct pharmacodynamic readout of whether a drug is suppressing active inflammation. That is why MS proof-of-concept trials can read out with under 100 patients in a matter of months, rather than the multi-year annualized-relapse-rate or disability-progression trials required for registration. Subcutaneous dosing was informed by dedicated PK, receptor occupancy, and immunogenicity studies published in 2025 [9] [10]. The design has one obvious weakness for commercial interpretation: no active comparator. Placebo-controlled lesion suppression will tell Zenas whether the drug works but not whether it works as well as ocrelizumab or ublituximab. The relevant benchmarks are quantitative: in the ocrelizumab Phase 2, the 600 mg arm produced an 89% reduction in gadolinium-enhancing lesions versus placebo at week 24 (95% CI 68-97%) and the 2000 mg arm produced 96% (95% CI 89-99%) [13]. In the ublituximab Phase 2a, gadolinium-enhancing lesions were reduced to zero at weeks 24 and 48 [14]. That is the bar. Cross-trial comparison against these historical CD20 controls will drive the market's read on whether obexelimab is competitive in MS.

Our model estimates a 5% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 30%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest failure mode. In MS, obexelimab needs to approach CD20 depletion on lesion suppression to be commercially relevant. Functional B-cell silencing has never been shown to equal depletion in a head-to-head trial, and there is a plausible mechanistic reason it might not: partial silencing may leave residual antigen-presenting function that keeps driving T-cell-mediated relapses. MoonStone will not answer this cleanly because it lacks an active comparator. Cross-indication read-throughs are mixed. The Phase 2 SLE trial (Merrill et al., Arthritis Rheumatol 2023, n=104 randomized) missed its primary endpoint, which was the proportion of patients reaching week 32 without loss of improvement (42.0% obexelimab vs 28.6% placebo, P=0.183) [11]. Time to loss of improvement was numerically better on obexelimab, and a prespecified gene-expression-defined 'cDx+' subgroup showed a BICLA response rate of 33% vs 12.5% in cDx- patients, which Zenas is now advancing in the current Phase 2 (NCT06559163) as biomarker-selected [11]. That is a legitimate biomarker rescue thesis but not a clean full-population win. The Phase 2 IgG4-RD pilot (Perugino et al., Lancet Rheumatol 2023) was open-label single-arm with strong response rates but no placebo control [12]. Neither is a clean win. Safety risk is moderate. Non-depleting B-cell modulation should carry lower infection risk than CD20 depletion, and the PK and receptor-occupancy studies published in 2025 in Clin Pharmacol Drug Dev and Adv Ther did not surface unusual signals [9] [10]. Subcutaneous dosing is patient-friendly. Commercial risk is severe. Even with a positive MoonStone, Zenas would face pricing pressure against ublituximab and generic rituximab, and payers will demand comparative-effectiveness data a Phase 2 lesion trial cannot provide. Financial and execution risk: as of June 30, 2026, Zenas held $673.9M in cash, cash equivalents, and investments, against a Q2 net loss of $111.5M and R&D spend of $62.9M in the quarter ($123.4M year-to-date) [7]. Management guides runway into Q2 2027, extendable into Q4 2027 upon obexelimab approval [7]. That funds Zenas comfortably through the MoonStone and INDIGO readouts but leaves little cushion beyond them. 2026 financing already included $75M in senior secured term debt, $230M in 2.50% convertible senior notes due 2032, $108M from a follow-on equity offering, and $71.5M via the ATM program [7], so the equity cost of a bad readout is already partly baked in. A negative INDIGO signal would force another dilutive raise in a hostile tape and compress optionality across the whole portfolio.

Worth watching, but MS is the weakest leg of the Zenas story. The signal that would change the picture: MoonStone showing lesion suppression in the neighborhood of what CD20 depleters delivered in Phase 2, meaning ≥80% reduction in new gadolinium-enhancing lesions versus placebo, which would be within striking distance of the 89% ocrelizumab put up at 600 mg [13]. Anything materially below that puts obexelimab in a follower position in MS with no differentiated efficacy claim, and the drug becomes a niche second-line option at best. The more important Zenas catalyst is the IgG4-RD Phase 3 (INDIGO, NCT05662241) readout expected in 2026 [2] [6]. IgG4-related disease has no approved therapy, high unmet need, orphan-sized population, and a mechanism (fibro-inflammatory disease driven by IgG4-producing plasmablasts that keep expressing CD19 after losing CD20) that maps directly to obexelimab's plasmablast-silencing pitch. That is the trial that could carry the stock and validate the platform. Scenario analysis on INDIGO. INDIGO hit + MoonStone hit: platform validated, MS becomes a real second wave, Zenas re-rates and the Q4 2027 approval-triggered runway extension kicks in. INDIGO hit + MoonStone miss: platform still validated on the anchor indication, MS quietly deprioritized, stock still supported by the IgG4-RD franchise and the wAIHA readout. INDIGO miss + MoonStone hit: real damage; the plasmablast-silencing thesis breaks on its cleanest test, MS becomes the story by default, and Zenas would need to raise from a weakened position with runway shortening from Q2 2027. INDIGO miss + MoonStone miss: catastrophic; single-asset biotech with a broken platform thesis, four parallel programs to wind down or repriotitize, and cash to Q2 2027 that becomes a going-concern discussion very quickly given the 2026 debt and convertible layer. SApHiAre in warm autoimmune hemolytic anemia is the second-line insurance policy on the mechanism [3]. Check back in Q3-Q4 2026 for the first readouts. The Zenas Q2 2026 10-Q filed 2026-08-13 is the current authoritative source on timeline guidance and cash runway [7].